Research Analysts Set Expectations for ETON Q3 Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – B. Riley lifted their Q3 2025 earnings per share (EPS) estimates for Eton Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. B. Riley analyst M. El-Saadi now forecasts that the company will post earnings of $0.14 per share for the quarter, up from their previous estimate of $0.04. B. Riley has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals’ Q4 2025 earnings at $0.25 EPS, FY2025 earnings at $0.44 EPS, FY2026 earnings at $1.08 EPS, FY2027 earnings at $1.45 EPS, FY2028 earnings at $1.66 EPS and FY2029 earnings at $1.82 EPS.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02). The firm had revenue of $11.65 million during the quarter, compared to the consensus estimate of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%.

Several other equities research analysts also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $33.00 price target on shares of Eton Pharmaceuticals in a report on Wednesday. Craig Hallum upped their price target on Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday.

Eton Pharmaceuticals Stock Down 3.8 %

NASDAQ ETON opened at $14.22 on Friday. The business has a 50 day moving average price of $15.58 and a 200-day moving average price of $11.58. Eton Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $18.41. The company has a market cap of $370.45 million, a price-to-earnings ratio of -64.64 and a beta of 1.37.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC bought a new position in Eton Pharmaceuticals in the 4th quarter valued at $86,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Eton Pharmaceuticals in the 3rd quarter valued at $54,000. Jefferies Financial Group Inc. bought a new position in Eton Pharmaceuticals in the 4th quarter valued at $133,000. Raymond James Financial Inc. bought a new position in Eton Pharmaceuticals in the 4th quarter valued at $147,000. Finally, Bank of America Corp DE grew its stake in Eton Pharmaceuticals by 5,422.4% in the 4th quarter. Bank of America Corp DE now owns 11,100 shares of the company’s stock valued at $148,000 after purchasing an additional 10,899 shares during the period. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.